CN108048471B - 一种具有抗肿瘤活性的三元复合毒素及其制备方法 - Google Patents

一种具有抗肿瘤活性的三元复合毒素及其制备方法 Download PDF

Info

Publication number
CN108048471B
CN108048471B CN201711373010.XA CN201711373010A CN108048471B CN 108048471 B CN108048471 B CN 108048471B CN 201711373010 A CN201711373010 A CN 201711373010A CN 108048471 B CN108048471 B CN 108048471B
Authority
CN
China
Prior art keywords
leu
glu
ala
ser
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711373010.XA
Other languages
English (en)
Other versions
CN108048471A (zh
Inventor
胡胜标
胡晓凤
谢亚丽
张国勇
杨曦
夏立秋
丁学知
彭智辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan Normal University
Original Assignee
Hunan Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan Normal University filed Critical Hunan Normal University
Priority to CN201711373010.XA priority Critical patent/CN108048471B/zh
Publication of CN108048471A publication Critical patent/CN108048471A/zh
Application granted granted Critical
Publication of CN108048471B publication Critical patent/CN108048471B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

一种具有抗肿瘤活性的三元复合毒素及其制备方法,本发明之具有抗肿瘤活性的三元复合毒素,其编码基因来源于昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01,为xsrfABC基因,xsrfABC基因包含三个开放阅读框:xsrfA、xsrfBxsrfCxsrfA的核苷酸序列如序列表SEQ ID NO:1所示,xsrfB的核苷酸序列如序列表SEQ ID NO:2所示,xsrfC的核苷酸序列如序列表SEQ ID NO:3所示。本发明还包括所述具有抗肿瘤活性的三元复合毒素的制备方法。本发明中,所得复合毒素XSrfABC对肿瘤细胞具有毒性,但对正常细胞没有毒性。

Description

一种具有抗肿瘤活性的三元复合毒素及其制备方法
技术领域
本发明涉及一种具有抗肿瘤活性的三元复合毒素及其制备方法。
背景技术
根据世界卫生组织统计,全世界有3/5的人死于恶性肿瘤、糖尿病、心血管疾病、慢性呼吸系统疾病这4大类疾病,而恶性肿瘤则是最主要的死因之一。微生物来源的抗肿瘤活性成分结构新颖、作用机制独特,具有很好的发展潜力。夏立秋等分离到一株具有肿瘤靶向性的昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01(CCTCC NO:M2012069),从中分离到了四种具有抗肿瘤活性的次级代谢产物——长沙霉素A、长沙霉素B、长沙霉素C、长沙霉素D;在进一步研究X.stockiae HN_xs01中抗肿瘤活性物质时,筛选到一种具有抗肿瘤活性的三元复合毒素。该三元复合毒素与细菌中普遍存在的SrfABC毒素具有同源性。目前,已有研究报道主要集中在SrfABC类毒素的所在基因岛序列特点、毒素表达调控研究上,有关SrfABC类毒素的认识还存在较大的分歧、矛盾性观点较多;而关于SrfABC毒素的抗肿瘤活性没有相关研究和报道。
发明内容
本发明的目的是,克服现有技术的不足,提供一种具有抗肿瘤活性的三元复合毒素及其制备方法。
本发明解决其技术问题采用的技术方案是,本发明之具有抗肿瘤活性的三元复合毒素,其编码基因来源于昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01(CCTCC NO:M2012069)(参见CN103074282A),为xsrfABC基因(即SrfABC毒素基因),xsrfABC基因包含三个开放阅读框(ORF):xsrfA(1395bp)、xsrfB(3021bp)和xsrfC(2682bp)。xsrfA的核苷酸序列如序列表SEQ ID NO:1所示,xsrfB的核苷酸序列如序列表SEQ ID NO:2所示,xsrfC的核苷酸序列如序列表SEQ ID NO:3所示。
SEQ ID NO:1
xsrfA:
Figure BDA0001514119500000021
Figure BDA0001514119500000031
SEQ ID NO:2
xsrfB:
Figure BDA0001514119500000032
Figure BDA0001514119500000041
Figure BDA0001514119500000051
SEQ ID NO:3
xsrfC:
Figure BDA0001514119500000052
Figure BDA0001514119500000061
Figure BDA0001514119500000071
本发明之具有抗肿瘤活性的三元复合毒素(XSrfABC)的氨基酸序列,xsrfA基因编码的蛋白氨基酸序列如序列表SEQ ID NO:4所示,xsrfB基因编码的蛋白氨基酸序列如序列表SEQ ID NO:5所示,xsrfC基因编码的蛋白氨基酸序列如序列表SEQ ID NO:6所示。xsrfA编码产物XSrfA由464个氨基酸组成,xsrfB编码产物XSrfB由1006个氨基酸组成,xsrfC编码产物XSrfC由893个氨基酸组成。
SEQ ID NO:4
XSrfA:
Figure BDA0001514119500000072
Figure BDA0001514119500000081
Figure BDA0001514119500000091
SEQ ID NO:5
XSrfB:
Figure BDA0001514119500000101
Figure BDA0001514119500000111
Figure BDA0001514119500000121
Figure BDA0001514119500000131
Figure BDA0001514119500000141
SEQ ID NO:6
XSrfC:
Figure BDA0001514119500000142
Figure BDA0001514119500000151
Figure BDA0001514119500000161
Figure BDA0001514119500000171
Figure BDA0001514119500000181
本发明还包括序列表SEQ ID NO:4-6所示的氨基酸序列以及编码这些氨基酸序列的核苷酸序列。
通过实验发现,XSrfABC复合毒素对肿瘤细胞具有很好的抑制效果。
本发明之具有抗肿瘤活性的三元复合毒素的制备方法:首先我们提取了Xenorhabdus stockiae HN_xs01的基因组,构建了基因组fosmid文库,筛选对Hela细胞具有毒性的克隆子,对克隆子进行测序分析,将xsrfABC基因克隆获得表达载体pSC101-BAD-xsrfABC,将表达载体转化入GB05,得到重组菌株GB05(XSrfABC),诱导表达XSrfABC毒素。可测定对肿瘤细胞的毒性(参见图1)。(从Xenorhabdus stockiae HN_xs01的基因组fosmid文库中筛选到xsrfABC基因,将xsrfABC基因诱导表达得到复合毒素)。
本发明中,GB05(XSrfABC)重组菌株经诱导后,提取全蛋白对肿瘤细胞Hela、B16进行毒性检测。与空白对照相比,诱导后全蛋白对细胞的影响更为明显,特别是诱导4h全蛋白造成细胞形态变圆,伪足消失,细胞结团,细胞贴壁性降低,细胞数目减少,说明诱导后全蛋白有明显的细胞毒性。说明XSrfABC毒素对肿瘤细胞具有很好的毒性。此外,本发明通过原核表达、纯化制备XSrfABC毒素,提供了一种新型的、细菌来源的抗肿瘤活性物质。XSrfABC毒素对正常细胞——人脐静脉内皮细胞(HUVEC)没有毒性。
本发明之具有抗肿瘤活性的三元复合毒素,还可以采用以下方法制备:(将三个基因片断分别表达三种蛋白,再收集,即得到复合毒素)
为了制备XSrfABC毒素,我们分别构建了XSrfA、XSrfB和XSrfC的原核表达载体,诱导表达复合毒素的各组分,并利用亲和层析纯化毒素蛋白,将三种组分混合后以Hela细胞为靶标进行细胞毒性测定。具体过程:PCR分别扩增xsrfA、xsrfB和xsrfC基因片段,并克隆到表达质粒pGEX-4T-2,获得三个重组质粒:pGEX-4T-srfA,pGEX-4T-srfB,pGEX-4T-srfC(参见图2)。
将三个重组质粒分别电转至E.coli BL21中,获得重组菌株BL21-SrfA、BL21-SrfB、BL21-SrfC。三种重组菌株经IPTG诱导后,均表达可溶性的目的蛋白。将三种可溶性表达蛋白的菌体上清用0.22μm滤膜过滤,用清洗缓冲液清洗GST琼脂糖树脂,加入蛋白裂解液,加入5倍柱体积的洗涤缓冲液洗脱蛋白,重复洗脱一次,加入2倍柱体积Elution buffer洗脱,收集蛋白,SDS-PAGE检测所纯化蛋白的纯度(参见图3)。分别表达再收集的复合毒素。
诱导后复合毒素对肿瘤细胞有明显的细胞毒性。但对正常细胞——人脐静脉内皮细胞(HUVEC)没有毒性。
微生物来源说明
昆虫病原线虫共生致病杆菌HN_xs01(Xenorhabdus stockiae HN_xs01);于2012年03月09日在中国典型培养物保藏中心(简称CCTCC,地址:中国·武汉·武汉大学)保藏,菌种保藏编号为CCTCC NO:M 2012069。(参见CN103074282A)
附图说明
图1为表达质粒pSC101-BAD-xsrfABC示意图;
图2为表达质粒pGEX-4T-xsrfA、pGEX-4T-xsrfB、pGEX-4T-xsrfC示意图;
图3为毒素蛋白XSrfA、XSrfB、XSrfC可溶性表达及纯化检测图;
图4为毒素蛋白XSrfABC对Hela细胞的毒性;图中,A,对照(PBS处理肿瘤细胞);B~F,实验组(毒素蛋白XSrfABC的浓度分别为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl);
图5为毒素蛋白XSrfABC对B16细胞的毒性;图中,A,对照(PBS处理肿瘤细胞);B~F,实验组(毒素蛋白XSrfABC的浓度分别为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl);
图6为毒素蛋白XSrfABC对人脐静脉内皮细胞(HUVEC)的毒性;图中,A,对照(PBS处理人脐静脉内皮细胞细胞);B~F,实验组(毒素蛋白XSrfABC的浓度分别为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl)。
具体实施方式
以下结合具体实施例对本发明作进一步详细说明。
实施例1
本实施例之具有抗肿瘤活性的三元复合毒素,其编码基因来源于昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01(CCTCC NO:M2012069)(参见CN103074282A),为xsrfABC基因(即SrfABC毒素基因),xsrfABC基因包含三个开放阅读框(ORF):xsrfA(1395bp)、xsrfB(3021bp)和xsrfC(2682bp)。xsrfA的核苷酸序列如序列表SEQ ID NO:1所示,xsrfB的核苷酸序列如序列表SEQ ID NO:2所示,xsrfC的核苷酸序列如序列表SEQ IDNO:3所示。
本实施例之具有抗肿瘤活性的三元复合毒素(XSrfABC)的氨基酸序列,xsrfA基因编码的蛋白氨基酸序列如序列表SEQ ID NO:4所示,xsrfB基因编码的蛋白氨基酸序列如序列表SEQ ID NO:5所示,xsrfC基因编码的蛋白氨基酸序列如序列表SEQ ID NO:6所示。xsrfA编码产物XSrfA由464个氨基酸组成,xsrfB编码产物XSrfB由1006个氨基酸组成,xsrfC编码产物XSrfC由893个氨基酸组成。
致病杆菌基因组Fosmid文库构建
制备昆虫病原线虫共生致病杆菌HN_xs01(Xenorhabdus stockiae HN_xs01)过夜菌,提取基因组;用200μL的枪头进行机械剪切50次~100次,回收取目的DNA片段。将基因组DNA末端补齐及磷酸化修复,与载体pCC1FO进行连接,进行噬菌体包装,并感染EPI300-T1R,稀释涂板,涂布在含Cm 12.5μg/mL的LB固体平板上,37℃倒置培养,待克隆子长出。待克隆子都长出,进行计数并做好记录,加2mL LB培养基于第一个平板上,将菌落洗脱下来后吸入另外一个平板上,每两个平板的洗脱液吸入同一个2mL的EP管中,加上终浓度为10wt%的甘油保菌,-80℃保存。
实施例2对肿瘤细胞具有毒性的克隆子筛选
从液氮罐里面取出肿瘤细胞(Hela细胞和B16细胞)冻存管,于37℃水浴锅中快速来回划动使其融化,加入7mL 1640培养基后,放入37℃培养。肿瘤细胞生长24h后倒掉废液,用3mL PBS(磷酸盐缓冲液)洗涤两次后加入1mL0.25wt%的胰酶于37℃消化30s,加入4mL新鲜培养基终止酶的反应,将细胞按“Z”字打散,1000rpm离心5min,将上清倒掉后加入8mL培养基将细胞悬浮后全部转移到培养皿中,37℃培养。
取出实施例1中所得致病杆菌基因组Fosmid文库克隆管,分别取10μL接种于20mL含Cm(氯霉素)12.5μg/mL的LB液体培养基中,37℃振荡培养24h;离心收集上述菌体,用去离子水洗涤两次,加入2mL去离子水混匀,进行超声破碎;离心收集上清,将上清溶液通过0.22μm滤膜在超净台中进行过滤,取50μL上清液作用于各肿瘤细胞,筛选出对肿瘤细胞有毒性的Fosmid克隆;对克隆子进行测序分析。
实施例3表达载体pSC101-BAD-xsrfABC的构建
设计引物(hyg-pBAD-F:ACGCGGATCCACCTGCAGTGTTACATTGC;hyg-pBAD-R:ACGCGTCGACATAGTGAATTCCTCCTGCTAGC),采用高保真Taq酶扩增xsrfABC基因的ORF,扩增反应的条件为94℃5min,(94℃30s,56℃30s,72℃4min)共30个循环,72℃10min。BamH I和SalI双酶切后将其克隆到实验室保存的pSC101-BAD-hyg质粒上,转化大肠杆菌宿主GB05菌株,得到重组菌株GB05(XSrfABC),诱导表达XSrfABC毒素。并通过PCR鉴定挑选出转化阳性的克隆子,进一步通过测序鉴定。图1为表达质粒pSC101-BAD-xsrfABC示意图。
将XSrfABC毒素配制成不同浓度的溶液,将不同浓度的XSrfABC毒素蛋白加入肿瘤细胞和正常细胞中,培养48h后观察毒素对细胞的作用情况。
图4为毒素蛋白XSrfABC对Hela细胞的毒性;图中,A,对照(PBS处理细胞);B~F,实验组(毒素蛋白XSrfABC的浓度分别为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl);
图5为毒素蛋白XSrfABC对B16细胞的毒性;图中,A,对照(PBS处理细胞);B~F,实验组(毒素蛋白XSrfABC的浓度分别为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl)。
图6为毒素蛋白XSrfABC对人脐静脉内皮细胞(HUVEC)的毒性;图中,A,对照(PBS处理人脐静脉内皮细胞细胞);B~F,实验组(毒素蛋白XSrfABC的浓度分别为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl)。
可见复合毒素对两种肿瘤细胞具有毒性,对正常细胞正常。
实施例4表达质粒pGEX-4T-srfA,pGEX-4T-srfB,pGEX-4T-srfC的构建
分别设计引物(srfA-F:ACGCGGATCCATGTGTATTTTTAATAACAAGG,srfA-R:ACGCGTCGACTTAATCTGCCTCTCGCTTTATCG;srfB-F:ACGCGGATCCATGCTGGCAACTATTACTG,srfB-R:ACGCGTCGAC TTAGATTTTAATACTTCCAC;srfC-F:ACGCGGATCC ATGAATCATTTTACTCCTGAAC,srfC-R:ACGCGTCGAC TTACTCCGACGACAATTGAATACG),采用高保真Taq酶分别扩增xsrfA、xsrfB和xsrfC基因片段,扩增反应的条件为94℃5min,(94℃30s,56℃30s,72℃1~3min)共30个循环,72℃10min。BamH I和SalI双酶切后将其克隆到表达质粒pGEX-4T-2上,转化大肠杆菌宿主GB05菌株,并通过PCR鉴定挑选出转化阳性的克隆,进一步通过测序鉴定。得到重组菌株BL21(SrfA),BL21(SrfB),BL21(SrfC)。
实施例5XSrfABC毒素的可溶性表达及表达产物的纯化
将实施例4所得重组菌株BL21(SrfA),BL21(SrfB),BL21(SrfC)分别转接至LB液体培养基,37℃,160rpm培养过夜;按2wt%的接种量将过夜菌转接至50mLLB液体培养基中,37℃培养2h,使OD600为0.6,进行IPTG诱导。
结果表明,SrfA蛋白在IPTG(异丙基硫代半乳糖苷)浓度为0.5mM,16℃诱导14h,可以使蛋白可溶性表达的量达到最大;SrfB蛋白在IPTG浓度为0.5mM,16℃诱导过夜,可以使蛋白可溶性表达的量达到最大;SrfC蛋白在IPTG浓度为0.2mM,16℃诱导过夜,可以使蛋白可溶性表达的量达到最大。收集各菌体并超声破碎,收集上清液进行SDS-PAGE检测。分别以空载体pGEX-4T-2的菌体过夜诱导表达的上清为对照,在BL21(SrfA)上清中表达分子量81kDa的目的蛋白条带,在BL21(SrfB)上清中表达分子量为136kDa的目的蛋白条带,在BL21(SrfC)上清中表达分子量为124kDa的目的蛋白条带,表明SrfA,SrfB,SrfC在重组菌株中均得到了可溶性表达。将诱导表达后的三种蛋白的菌体上清用0.22μm滤膜过滤,用10倍柱体积的清洗缓冲液清洗GST琼脂糖树脂,加入蛋白裂解液5mL,封闭底部,4℃结合6h,加入5倍柱体积的洗涤缓冲液洗脱蛋白,重复洗脱一次,加入2倍柱体Elution buffer洗脱,收集蛋白,重复洗脱三次,收集洗脱液,进行SDS-PAGE检测。纯化结果SrfA,SrfB,SrfC蛋白纯度较高,三种蛋白的纯度均在96~98%之间。图2为表达质粒pGEX-4T-xsrfA、pGEX-4T-xsrfB、pGEX-4T-xsrfC示意图;图3为毒素蛋白XSrfA、XSrfB、XSrfC可溶性表达及纯化检测图。
从液氮罐里面取出肿瘤细胞(Hela细胞和B16细胞)冻存管,于37℃水浴锅中快速来回划动使其融化,加入7mL 1640培养基后,放入37℃培养24h,倒掉废液,用3mL PBS洗涤两次后加入1mL 0.25%的胰酶进行37℃消化30s,加入4mL新鲜培养基终止酶的反应,将细胞按“Z”字打散,1000rpm离心5min,将上清倒掉后加入8mL培养基将细胞悬浮后全部转移到培养皿中,37℃培养。待细胞状态极佳时,将细胞进行悬浮,通过血球计数板进行计数,加入培养基调整细胞悬液浓度(2×104细胞/mL),将调整好的细胞悬液按100μL/孔加入到96孔板中。
将毒素蛋白XSrfA、XSrfB、XSrfC混合后,配制浓度为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl的溶液,37℃孵育48h后观察毒素对正常细胞、Hela细胞和B16细胞的作用情况。结果表明,混合毒素对两种肿瘤细胞具有毒性,对正常细胞无素性。
将毒素蛋白XSrfA、XSrfB、XSrfC分别配制浓度为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl的溶液,分别于37℃孵育48h后观察毒素对正常细胞、Hela细胞和B16细胞的作用情况。结果表明,所有浓度的单独的毒素蛋白XSrfA或XSrfB或XSrfC对正常细胞、Hela细胞和B16细胞均没有毒性。
将毒素蛋白XSrfA、XSrfB混合,配制浓度为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl的溶液,分别于37℃孵育48h后观察毒素对正常细胞、Hela细胞和B16细胞的作用情况。结果表明,XSrfA、XSrfB混合蛋白对正常细胞、Hela细胞和B16细胞均没有毒性。
将毒素蛋白XSrfA、XSrfC混合,配制浓度为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl的溶液,分别于37℃孵育48h后观察毒素对正常细胞、Hela细胞和B16细胞的作用情况。结果表明,XSrfA、XSrfC混合蛋白对正常细胞、Hela细胞和B16细胞均没有毒性。
将毒素蛋白XSrfB、XSrfC混合,配制浓度为50ng/μl、100ng/μl、150ng/μl、200ng/μl、250ng/μl的溶液,分别于37℃孵育48h后观察毒素对正常细胞、Hela细胞和B16细胞的作用情况。结果表明,XSrfB、XSrfC混合蛋白对正常细胞、Hela细胞和B16细胞均没有毒性。
序列表
<110> 湖南师范大学
<120> 一种具有抗肿瘤活性的三元复合毒素及其制备方法
<160> 6
<210> 1
<211> 1395
<212> DNA
<213>昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01(CCTCC NO:M2012069)
<220>
<400>1
atgtgtattt ttaataacaa ggaacggttt accgtggaag aaacattttt acgtggtgat 60
aagctcgaaa gttatttgcc aatgggggag aatggtcagg ccgtccacct ttcggcacta 120
caactacgtg aaactttacg tttgcggcag ctttctgaag tagctaactc tctggctatt 180
ccgcaagtta atgaacaagg tgatcgtatt gattggtacg cgagcttttc cggtaatgtt 240
gttccttggg cggctgcaac ggatgatgaa cgtcaagctg cattgaaaca actggaagct 300
aataaagtgg caatcgagca actcagtgct caaatgttaa gtcaaaagac gcatgaaatg 360
cgtctttttg gggccttgtt gagtaagacg atacaatttc ctgataagga tcatgtatat 420
ttggtcgatg gtaaacccgt attgactttt tggggatttg tcaatgctca gcaacaggct 480
cgccctaatc cttttgattg cctaaaatta aaccgtcctg ctccctctaa tactggaaaa 540
tctactgata tcccgccagt tcctacaaca ctcgctaagc catctgtaaa aatagaagaa 600
gtaatttcaa tatcccgttc agcgggaaaa cagactcggc gttgggtaat accacgttgg 660
ttgtggtggg tgttacccat tttattgctt tttatcttac ttatgttagt gcgcggctgt 720
gtacccaatt ggtatttttg gggagtatca ccttccactc atcttgtttc tgaacttcca 780
atgcgggaag agaaaaattt gcaagatgga aaaagaatat tattaccacc agaaatagct 840
gtttctccgc cagagacaaa tactattgac tcaatgaatc caactttgtc tacacagtca 900
aatgtaccta ctacaccgac tgtaggcatg aattctacat ctggtaaggt atcaatacct 960
tcacctttat caacagccgc taatattccc cctgtattgt taacagttcc atctgttgat 1020
gcactagtga tccctgataa tgctgtacaa aaaggaaccg ttgattttct caatggacgt 1080
tggtacgcgg gagcaggaat tcaggatatc cgaacgggta aacccctaag attgatgtat 1140
caaattactg atggcaaagg atttgttgaa atggttcgtg gagatggtat tcgttgccaa 1200
gcacctgtca cagcggctat ggaatccggt agcttaaaat tggataacca tgatgaagca 1260
aagtgcagcg atggttcaac ttatactatg cctgaagtta tctgtcagtc agatagtcaa 1320
ggtgtaacgg cgtgcacagg acgctataac gaaaaaactt tatttcctat gtcgataaag 1380
cgagaggcag attaa 1395
<210>2
<211> 3021
<212> DNA
<213>昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01(CCTCC NO:M2012069)
<220>
<400>2
atgctggcaa ctattactga ttttaaagaa aaagttaccc tgattcgtga cagcggtatc 60
cagtttctgg attttgcttt tgcacttcct aaccgcaaaa tctacggcga attcttgctg 120
ggaggagaaa ataatccgct tattcgtctg gtgtacaatg aacgggaaga tacttttcag 180
gttcctgcct catcaggttc tgctgcattt tcagcagaac ctgattaccc attggcattg 240
gaaaagtcac ttgagattta taatgatatc tggttaccac tgccattctt ccgttttaac 300
tccccaaaat gttttgctca ggggccaact aactggtcac gaataaaatt tcatgcactt 360
gatacaccgg atgaacaagg aaatacgtgg cgcgtcactt tggcttttga taccaaagtt 420
cttccagaca gaaggaatac gcaatatctg gctccctgtg atgatgatgt ccgttctggg 480
gtgggttttg cactggcaga aaatcaccat gaaatgggag attttctgtt attgaggtgg 540
gtagatgatt ggttacggga aagctattcc gagcgtgcgg cttcattgtg gcgtttatat 600
catgaagata ttgagcacaa tctgaatcag agggaacacc aggggcatta tcttaattta 660
attaacgctc ttaatgtgtt attgcaagtt cctgacatcc agctcaatga tgtcaaactt 720
cagaataacc caattaatgt tgatttagtg cttgatgtag gcaactcacg tagttgtggg 780
attttaattg aagaacaccg ggatgataac cagggattat ctcaaaaata tcaattgcag 840
ttgcgtgact taagtgagcc tcagtatgtt tatacggagc cgtttgacag tcggcttgaa 900
tttgctcagg cagaatttgg taaacaggat ttttctgcta aaagtggccg tagtgatgct 960
tttacctggc caactattgg tcgggtagga gaggaagcct tccgcatggc atcccaacgc 1020
ttgggaacag aagggtcaac agggctttcc agtccaaaac gttatttgtg ggatgaggcg 1080
ccttattctc cggggtggcg ttttagtcgc gcttttgtga aatcggatcg tgaacctcag 1140
gcaacagcgg caccgatgac ttatatgatc aatgataaag gtgaggcttt gtatgcgtta 1200
aaaccttctg aacgtatgcc tgtgtttact ccagattata gccgcagctc cctgatgacg 1260
atgatgttat ctgaagtatt agctcaagcg ttgatgcaga ttaacagccc ggcacagcgt 1320
ttgaagatga gtcatgccag tactcctcgc cagctaaata acatcatcct taccgtacca 1380
ccatctatgc ctaagccgga gcgtgcaatt ttccagcagg cgatgatgca ggcaatcaga 1440
ctggtctgga aggcattggg gtgggaggaa atggatcagg gagtggatga aagcggaaga 1500
gaagaacaaa acgttttgcg taaacgtatt ctaccggaag tgcatgtaaa atgggacgaa 1560
gcgacttgcg gtcagctggt ttatctttat aacgaaaccc aaaattactt tggtggccga 1620
agtgaggagt tttttgctgc aacaatccgt ccggataacc gagcagaaac tggtgataca 1680
cgaacattaa aaattgcttc gattgatatt ggtggtggaa caaccgattt agtagtcacc 1740
cgctatacct tagatgatgg caatggtagc aatgtacgta ttgtaccgac acagctattt 1800
cgtgaaggct ttaaagttgc cggtgacgat attttattag atatcatcca attctattta 1860
cagcccgcat ttaaggccgc attgttgaat atcggctatc aggatttaga tgcagaagcg 1920
gtgatgtcgc gtctgtttgg cagcgaagca ttggatgctg gtaaacaggt attgcgtcag 1980
caactgacat tgcagatatt ttcacctata gcactggcta ttctgcatcg ctatgagaaa 2040
tttaccccag gctccagtga gcaggttatt agtacaacat ttggtgagtt actcccccat 2100
ctgcctacag ataaggtatg tagctatgtg gatgatgaag ttaaacgttg tttaccgata 2160
gggaacaata actcgttttc aatacttgat gtgccgttga atatcaattt gacgcagctt 2220
cataatgagt ttattgatgc ctacaatatt cgtttcaata tttgtcatag cctgcgagcg 2280
ttgtgtgaag tgctttggta ttacaattgc gatatgttgt tattaaccgg gcgtccctct 2340
cgtttacccg gaattcaggc actaatccgt cagctacagc cagttcctcc tgcccgtatc 2400
ctccctttac atggttatga aactgggggg tggtatccgt tcaataagaa aggtctgatt 2460
gaagatccta aatccactgc ggcggtgggc gcaatgttgt gtcttctggc ggaaaaatca 2520
cgtctgagta atttttactt ccgtactgcc aattttaagc cttattcaac aatccgttat 2580
ctgggaatgc ttgacagtaa caacttgttg aaagacagca acgtgtttta tagaaacatt 2640
gatttagaca catcaggatt ccaattggat aatcaccaat actttgaagt acgtggtgaa 2700
atgcgaatcg gttttcgcca gcttgataac gaacgttggc ctgcgacgcc actgtatact 2760
ttaaaaattc cgggggcacg tttagcgacg gctttatctg gtgatgcagt attgaggctg 2820
aagctggaag tagaagaggg acgtgggcca gatgcagaag ctaatggcag ccctgaaaaa 2880
ttccgtatca gtgaaataga tattgttggt tctgaacaaa atcctcgtaa gcaggatatt 2940
agttttaaat tgaatacatt agccggcaat ggactgggtg aaattcatta ttggctcgac 3000
agtggaagta ttaaaatcta a 3021
<210>3
<211> 2682
<212> DNA
<213>昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01(CCTCC NO:M2012069)
<220>
<400>3
atgaatcatt ttactcctga acagttaaaa agagagtggc ttagtgttgc ggaaggtgca 60
aatcaggcga ttgaatggat tgacgatgtt cgtgaaaatg caccacgtct caatactgaa 120
gcagaacgat taaagctgaa attacgccgt agccggaata cagcacaaag gctggcaacg 180
gcagctatgc gtcccatgac catcggtttt tttggccttt ctcaagcggg gaaatcctat 240
ctgatttctt cattagccgc tggggataat gggcggttag agacccaaat ggggcagcac 300
caactggatt ttatcgagca tattaatcca ccaggtggtg gcaaagaggc aacaggatta 360
gtgacacgtt ttagccgtca atcacattcg tccaatccag actggccgat tgaattgctg 420
ctatttaatg aagtggaaat cgctaagatc ttcgcgaata cgttcattca tgatttcaat 480
caggaaaaga ttgactggag ttatgatgaa aaacgtatag gtgatttact tacctcacta 540
aataaccgcc gtcaggcacg gaaagtatca ggtttaacgg aagatgatgt ggtctcgctg 600
tgggactatc tgattcgtca tgcggaaaaa agccagagta aaatggcatt gcaatactgg 660
cctgcagcgg tggagctcgc accatggtta tcgattgatg accgagcgca gctgttcggt 720
gaattatggg ggaatatcgg tgaattcaca gaggcttatc gtcgctttgc gcatacatta 780
cagcgtctgg gaggggctag tgtcgtcaga gcaccgctta atgtcttagt cattgagcaa 840
aatggccgat tagtacagag taacagcatt atgaatgtcg atatgctgga acgccttaac 900
aaaagtaatg atctacaggt agaggtatgt cctgagctgg agaatgggct atctgcacct 960
gtatctcttt ctttggctga acttacagca ttgacagtag aactacatgt tcctctactt 1020
tcgtctacac aagaaagatt atttgaagat gtcgatttat tggatttccc cggttaccgc 1080
gggcgtctgg gagtggagtc taccgcttat tttcagcaaa tgactgaaaa cgatgacagc 1140
aacccactgg cacagttgat tctgcgtggc aaagtggctt atttgtttga gcgttatacc 1200
gtcaatcagg aaatgaatgt tttagtcgtt tgtaccccct cgaatgaaca atctaacgtg 1260
aaagatgttg gtggagtact tgacgagtgg atccgttata cccaaggagt ggatgctgta 1320
agccgttccc gtcgtccatc gggattagtt tgggcaatca ctaaactcga tttacggatc 1380
acccaagagc tgaataaatc agaagatatg ttacgtgagg tgtggggaca gggtggaatg 1440
gtcaaaatca ccatgaccga acgtttcggc cattttccat ggatgcaaga atggcagact 1500
gattgtgctt ttaacaatac ttttctggta cgtaaaccac gtcaggctac accatttatt 1560
atgatgaaag agggaaatga agttggactc aatcaggaaa ctgaaccaaa actgtccttg 1620
atgaaaaaaa cctttctgga agatagtgct attcagcgtc atatcgcttt cccggatcag 1680
gcatgggatg ccatgttgca gctaaatgat ggtggtatgc gtcgattggc agactattta 1740
gctactgtcg cccagcgtga aatcaagtta gaacgtattg ctgaacagtt acatgaaacc 1800
cgccatgaat tgattgaagg aaatttaatc gcatggtttc agcaggataa tgcggaagaa 1860
tccgccaaaa aagagcgtat tgcagatgat attctcaagg tgttacagcg tcgggtggga 1920
atgcatggtg aattactggt gagtttgatc cctcaacgga aagcactaca agagctttat 1980
atgcaggaaa ctccgttgga attacctgat gatgataagg caagtaatga atcaatcgcg 2040
accttcggga ttggcagcga ttttgatctg ttcagcgata catcagatga aagtatatca 2100
gcactcagcc atgaacaaat gtttgctcag caggtaatta agttatgggt taattacctg 2160
cgtaccgtac cagaacagac gaacgtgaca aattttatcg gccttccccg accaataatt 2220
gaaacactgg tggatgaatt gatcactgcg atccagagaa tggatattga aggtgaattg 2280
gtaaatgtat tagcaaatac agaacaagca ggtgtgcgtc gggagaaaat ggtggaacgt 2340
caggtatccc gtgtgttgaa cgtcataaac gatttcatca cttggctggg ataccaaaaa 2400
atcacgaaag aaaaacggcc ggtgagcaaa tataacaaag ggcatcccct cttttccggc 2460
cctaataaac atgatccggc attgtggaaa gacgatggac atttgtaccg tttgacaagc 2520
gaaccactga gctatagcgc catgtttatc tttgattggt tgatcggtct gaaagaaatg 2580
attaaagaaa atgtcggtca ctctgccgga cgcgaaataa cggcggctca aaacgaacgg 2640
ctgggcacca ttattgaacg tattcaattg tcgtcggagt aa 2682
<210>4
<211> 464
<212> PRT
<213>人工序列
<220>
<400>4
Met Cys Ile Phe Asn Asn Lys Glu Arg Phe Thr Val Glu Glu Thr Phe
1 5 10 15
Leu Arg Gly Asp Lys Leu Glu Ser Tyr Leu Pro Met Gly Glu Asn Gly
20 25 30
Gln Ala Val His Leu Ser Ala Leu Gln Leu Arg Glu Thr Leu Arg Leu
35 40 45
Arg Gln Leu Ser Glu Val Ala Asn Ser Leu Ala Ile Pro Gln Val Asn
50 55 60
Glu Gln Gly Asp Arg Ile Asp Trp Tyr Ala Ser Phe Ser Gly Asn Val
65 70 75 80
Val Pro Trp Ala Ala Ala Thr Asp Asp Glu Arg Gln Ala Ala Leu Lys
85 90 95
Gln Leu Glu Ala Asn Lys Val Ala Ile Glu Gln Leu Ser Ala Gln Met
100 105 110
Leu Ser Gln Lys Thr His Glu Met Arg Leu Phe Gly Ala Leu Leu Ser
115 120 125
Lys Thr Ile Gln Phe Pro Asp Lys Asp His Val Tyr Leu Val Asp Gly
130 135 140
Lys Pro Val Leu Thr Phe Trp Gly Phe Val Asn Ala Gln Gln Gln Ala
145 150 155 160
Arg Pro Asn Pro Phe Asp Cys Leu Lys Leu Asn Arg Pro Ala Pro Ser
165 170 175
Asn Thr Gly Lys Ser Thr Asp Ile Pro Pro Val Pro Thr Thr Leu Ala
180 185 190
Lys Pro Ser Val Lys Ile Glu Glu Val Ile Ser Ile Ser Arg Ser Ala
195 200 205
Gly Lys Gln Thr Arg Arg Trp Val Ile Pro Arg Trp Leu Trp Trp Val
210 215 220
Leu Pro Ile Leu Leu Leu Phe Ile Leu Leu Met Leu Val Arg Gly Cys
225 230 235 240
Val Pro Asn Trp Tyr Phe Trp Gly Val Ser Pro Ser Thr His Leu Val
245 250 255
Ser Glu Leu Pro Met Arg Glu Glu Lys Asn Leu Gln Asp Gly Lys Arg
260 265 270
Ile Leu Leu Pro Pro Glu Ile Ala Val Ser Pro Pro Glu Thr Asn Thr
275 280 285
Ile Asp Ser Met Asn Pro Thr Leu Ser Thr Gln Ser Asn Val Pro Thr
290 295 300
Thr Pro Thr Val Gly Met Asn Ser Thr Ser Gly Lys Val Ser Ile Pro
305 310 315 320
Ser Pro Leu Ser Thr Ala Ala Asn Ile Pro Pro Val Leu Leu Thr Val
325 330 335
Pro Ser Val Asp Ala Leu Val Ile Pro Asp Asn Ala Val Gln Lys Gly
340 345 350
Thr Val Asp Phe Leu Asn Gly Arg Trp Tyr Ala Gly Ala Gly Ile Gln
355 360 365
Asp Ile Arg Thr Gly Lys Pro Leu Arg Leu Met Tyr Gln Ile Thr Asp
370 375 380
Gly Lys Gly Phe Val Glu Met Val Arg Gly Asp Gly Ile Arg Cys Gln
385 390 395 400
Ala Pro Val Thr Ala Ala Met Glu Ser Gly Ser Leu Lys Leu Asp Asn
405 410 415
His Asp Glu Ala Lys Cys Ser Asp Gly Ser Thr Tyr Thr Met Pro Glu
420 425 430
Val Ile Cys Gln Ser Asp Ser Gln Gly Val Thr Ala Cys Thr Gly Arg
435 440 445
Tyr Asn Glu Lys Thr Leu Phe Pro Met Ser Ile Lys Arg Glu Ala Asp
450 455 460
<210>5
<211> 1006
<212> PRT
<213>人工序列
<220>
<400>5
Met Leu Ala Thr Ile Thr Asp Phe Lys Glu Lys Val Thr Leu Ile Arg
1 5 10 15
Asp Ser Gly Ile Gln Phe Leu Asp Phe Ala Phe Ala Leu Pro Asn Arg
20 25 30
Lys Ile Tyr Gly Glu Phe Leu Leu Gly Gly Glu Asn Asn Pro Leu Ile
35 40 45
Arg Leu Val Tyr Asn Glu Arg Glu Asp Thr Phe Gln Val Pro Ala Ser
50 55 60
Ser Gly Ser Ala Ala Phe Ser Ala Glu Pro Asp Tyr Pro Leu Ala Leu
65 70 75 80
Glu Lys Ser Leu Glu Ile Tyr Asn Asp Ile Trp Leu Pro Leu Pro Phe
85 90 95
Phe Arg Phe Asn Ser Pro Lys Cys Phe Ala Gln Gly Pro Thr Asn Trp
100 105 110
Ser Arg Ile Lys Phe His Ala Leu Asp Thr Pro Asp Glu Gln Gly Asn
115 120 125
Thr Trp Arg Val Thr Leu Ala Phe Asp Thr Lys Val Leu Pro Asp Arg
130 135 140
Arg Asn Thr Gln Tyr Leu Ala Pro Cys Asp Asp Asp Val Arg Ser Gly
145 150 155 160
Val Gly Phe Ala Leu Ala Glu Asn His His Glu Met Gly Asp Phe Leu
165 170 175
Leu Leu Arg Trp Val Asp Asp Trp Leu Arg Glu Ser Tyr Ser Glu Arg
180 185 190
Ala Ala Ser Leu Trp Arg Leu Tyr His Glu Asp Ile Glu His Asn Leu
195 200 205
Asn Gln Arg Glu His Gln Gly His Tyr Leu Asn Leu Ile Asn Ala Leu
210 215 220
Asn Val Leu Leu Gln Val Pro Asp Ile Gln Leu Asn Asp Val Lys Leu
225 230 235 240
Gln Asn Asn Pro Ile Asn Val Asp Leu Val Leu Asp Val Gly Asn Ser
245 250 255
Arg Ser Cys Gly Ile Leu Ile Glu Glu His Arg Asp Asp Asn Gln Gly
260 265 270
Leu Ser Gln Lys Tyr Gln Leu Gln Leu Arg Asp Leu Ser Glu Pro Gln
275 280 285
Tyr Val Tyr Thr Glu Pro Phe Asp Ser Arg Leu Glu Phe Ala Gln Ala
290 295 300
Glu Phe Gly Lys Gln Asp Phe Ser Ala Lys Ser Gly Arg Ser Asp Ala
305 310 315 320
Phe Thr Trp Pro Thr Ile Gly Arg Val Gly Glu Glu Ala Phe Arg Met
325 330 335
Ala Ser Gln Arg Leu Gly Thr Glu Gly Ser Thr Gly Leu Ser Ser Pro
340 345 350
Lys Arg Tyr Leu Trp Asp Glu Ala Pro Tyr Ser Pro Gly Trp Arg Phe
355 360 365
Ser Arg Ala Phe Val Lys Ser Asp Arg Glu Pro Gln Ala Thr Ala Ala
370 375 380
Pro Met Thr Tyr Met Ile Asn Asp Lys Gly Glu Ala Leu Tyr Ala Leu
385 390 395 400
Lys Pro Ser Glu Arg Met Pro Val Phe Thr Pro Asp Tyr Ser Arg Ser
405 410 415
Ser Leu Met Thr Met Met Leu Ser Glu Val Leu Ala Gln Ala Leu Met
420 425 430
Gln Ile Asn Ser Pro Ala Gln Arg Leu Lys Met Ser His Ala Ser Thr
435 440 445
Pro Arg Gln Leu Asn Asn Ile Ile Leu Thr Val Pro Pro Ser Met Pro
450 455 460
Lys Pro Glu Arg Ala Ile Phe Gln Gln Ala Met Met Gln Ala Ile Arg
465 470 475 480
Leu Val Trp Lys Ala Leu Gly Trp Glu Glu Met Asp Gln Gly Val Asp
485 490 495
Glu Ser Gly Arg Glu Glu Gln Asn Val Leu Arg Lys Arg Ile Leu Pro
500 505 510
Glu Val His Val Lys Trp Asp Glu Ala Thr Cys Gly Gln Leu Val Tyr
515 520 525
Leu Tyr Asn Glu Thr Gln Asn Tyr Phe Gly Gly Arg Ser Glu Glu Phe
530 535 540
Phe Ala Ala Thr Ile Arg Pro Asp Asn Arg Ala Glu Thr Gly Asp Thr
545 550 555 560
Arg Thr Leu Lys Ile Ala Ser Ile Asp Ile Gly Gly Gly Thr Thr Asp
565 570 575
Leu Val Val Thr Arg Tyr Thr Leu Asp Asp Gly Asn Gly Ser Asn Val
580 585 590
Arg Ile Val Pro Thr Gln Leu Phe Arg Glu Gly Phe Lys Val Ala Gly
595 600 605
Asp Asp Ile Leu Leu Asp Ile Ile Gln Phe Tyr Leu Gln Pro Ala Phe
610 615 620
Lys Ala Ala Leu Leu Asn Ile Gly Tyr Gln Asp Leu Asp Ala Glu Ala
625 630 635 640
Val Met Ser Arg Leu Phe Gly Ser Glu Ala Leu Asp Ala Gly Lys Gln
645 650 655
Val Leu Arg Gln Gln Leu Thr Leu Gln Ile Phe Ser Pro Ile Ala Leu
660 665 670
Ala Ile Leu His Arg Tyr Glu Lys Phe Thr Pro Gly Ser Ser Glu Gln
675 680 685
Val Ile Ser Thr Thr Phe Gly Glu Leu Leu Pro His Leu Pro Thr Asp
690 695 700
Lys Val Cys Ser Tyr Val Asp Asp Glu Val Lys Arg Cys Leu Pro Ile
705 710 715 720
Gly Asn Asn Asn Ser Phe Ser Ile Leu Asp Val Pro Leu Asn Ile Asn
725 730 735
Leu Thr Gln Leu His Asn Glu Phe Ile Asp Ala Tyr Asn Ile Arg Phe
740 745 750
Asn Ile Cys His Ser Leu Arg Ala Leu Cys Glu Val Leu Trp Tyr Tyr
755 760 765
Asn Cys Asp Met Leu Leu Leu Thr Gly Arg Pro Ser Arg Leu Pro Gly
770 775 780
Ile Gln Ala Leu Ile Arg Gln Leu Gln Pro Val Pro Pro Ala Arg Ile
785 790 795 800
Leu Pro Leu His Gly Tyr Glu Thr Gly Gly Trp Tyr Pro Phe Asn Lys
805 810 815
Lys Gly Leu Ile Glu Asp Pro Lys Ser Thr Ala Ala Val Gly Ala Met
820 825 830
Leu Cys Leu Leu Ala Glu Lys Ser Arg Leu Ser Asn Phe Tyr Phe Arg
835 840 845
Thr Ala Asn Phe Lys Pro Tyr Ser Thr Ile Arg Tyr Leu Gly Met Leu
850 855 860
Asp Ser Asn Asn Leu Leu Lys Asp Ser Asn Val Phe Tyr Arg Asn Ile
865 870 875 880
Asp Leu Asp Thr Ser Gly Phe Gln Leu Asp Asn His Gln Tyr Phe Glu
885 890 895
Val Arg Gly Glu Met Arg Ile Gly Phe Arg Gln Leu Asp Asn Glu Arg
900 905 910
Trp Pro Ala Thr Pro Leu Tyr Thr Leu Lys Ile Pro Gly Ala Arg Leu
915 920 925
Ala Thr Ala Leu Ser Gly Asp Ala Val Leu Arg Leu Lys Leu Glu Val
930 935 940
Glu Glu Gly Arg Gly Pro Asp Ala Glu Ala Asn Gly Ser Pro Glu Lys
945 950 955 960
Phe Arg Ile Ser Glu Ile Asp Ile Val Gly Ser Glu Gln Asn Pro Arg
965 970 975
Lys Gln Asp Ile Ser Phe Lys Leu Asn Thr Leu Ala Gly Asn Gly Leu
980 985 990
Gly Glu Ile His Tyr Trp Leu Asp Ser Gly Ser Ile Lys Ile
995 1000 1005
<210>6
<211> 893
<212> PRT
<213>人工序列
<220>
<400>6
Met Asn His Phe Thr Pro Glu Gln Leu Lys Arg Glu Trp Leu Ser Val
1 5 10 15
Ala Glu Gly Ala Asn Gln Ala Ile Glu Trp Ile Asp Asp Val Arg Glu
20 25 30
Asn Ala Pro Arg Leu Asn Thr Glu Ala Glu Arg Leu Lys Leu Lys Leu
35 40 45
Arg Arg Ser Arg Asn Thr Ala Gln Arg Leu Ala Thr Ala Ala Met Arg
50 55 60
Pro Met Thr Ile Gly Phe Phe Gly Leu Ser Gln Ala Gly Lys Ser Tyr
65 70 75 80
Leu Ile Ser Ser Leu Ala Ala Gly Asp Asn Gly Arg Leu Glu Thr Gln
85 90 95
Met Gly Gln His Gln Leu Asp Phe Ile Glu His Ile Asn Pro Pro Gly
100 105 110
Gly Gly Lys Glu Ala Thr Gly Leu Val Thr Arg Phe Ser Arg Gln Ser
115 120 125
His Ser Ser Asn Pro Asp Trp Pro Ile Glu Leu Leu Leu Phe Asn Glu
130 135 140
Val Glu Ile Ala Lys Ile Phe Ala Asn Thr Phe Ile His Asp Phe Asn
145 150 155 160
Gln Glu Lys Ile Asp Trp Ser Tyr Asp Glu Lys Arg Ile Gly Asp Leu
165 170 175
Leu Thr Ser Leu Asn Asn Arg Arg Gln Ala Arg Lys Val Ser Gly Leu
180 185 190
Thr Glu Asp Asp Val Val Ser Leu Trp Asp Tyr Leu Ile Arg His Ala
195 200 205
Glu Lys Ser Gln Ser Lys Met Ala Leu Gln Tyr Trp Pro Ala Ala Val
210 215 220
Glu Leu Ala Pro Trp Leu Ser Ile Asp Asp Arg Ala Gln Leu Phe Gly
225 230 235 240
Glu Leu Trp Gly Asn Ile Gly Glu Phe Thr Glu Ala Tyr Arg Arg Phe
245 250 255
Ala His Thr Leu Gln Arg Leu Gly Gly Ala Ser Val Val Arg Ala Pro
260 265 270
Leu Asn Val Leu Val Ile Glu Gln Asn Gly Arg Leu Val Gln Ser Asn
275 280 285
Ser Ile Met Asn Val Asp Met Leu Glu Arg Leu Asn Lys Ser Asn Asp
290 295 300
Leu Gln Val Glu Val Cys Pro Glu Leu Glu Asn Gly Leu Ser Ala Pro
305 310 315 320
Val Ser Leu Ser Leu Ala Glu Leu Thr Ala Leu Thr Val Glu Leu His
325 330 335
Val Pro Leu Leu Ser Ser Thr Gln Glu Arg Leu Phe Glu Asp Val Asp
340 345 350
Leu Leu Asp Phe Pro Gly Tyr Arg Gly Arg Leu Gly Val Glu Ser Thr
355 360 365
Ala Tyr Phe Gln Gln Met Thr Glu Asn Asp Asp Ser Asn Pro Leu Ala
370 375 380
Gln Leu Ile Leu Arg Gly Lys Val Ala Tyr Leu Phe Glu Arg Tyr Thr
385 390 395 400
Val Asn Gln Glu Met Asn Val Leu Val Val Cys Thr Pro Ser Asn Glu
405 410 415
Gln Ser Asn Val Lys Asp Val Gly Gly Val Leu Asp Glu Trp Ile Arg
420 425 430
Tyr Thr Gln Gly Val Asp Ala Val Ser Arg Ser Arg Arg Pro Ser Gly
435 440 445
Leu Val Trp Ala Ile Thr Lys Leu Asp Leu Arg Ile Thr Gln Glu Leu
450 455 460
Asn Lys Ser Glu Asp Met Leu Arg Glu Val Trp Gly Gln Gly Gly Met
465 470 475 480
Val Lys Ile Thr Met Thr Glu Arg Phe Gly His Phe Pro Trp Met Gln
485 490 495
Glu Trp Gln Thr Asp Cys Ala Phe Asn Asn Thr Phe Leu Val Arg Lys
500 505 510
Pro Arg Gln Ala Thr Pro Phe Ile Met Met Lys Glu Gly Asn Glu Val
515 520 525
Gly Leu Asn Gln Glu Thr Glu Pro Lys Leu Ser Leu Met Lys Lys Thr
530 535 540
Phe Leu Glu Asp Ser Ala Ile Gln Arg His Ile Ala Phe Pro Asp Gln
545 550 555 560
Ala Trp Asp Ala Met Leu Gln Leu Asn Asp Gly Gly Met Arg Arg Leu
565 570 575
Ala Asp Tyr Leu Ala Thr Val Ala Gln Arg Glu Ile Lys Leu Glu Arg
580 585 590
Ile Ala Glu Gln Leu His Glu Thr Arg His Glu Leu Ile Glu Gly Asn
595 600 605
Leu Ile Ala Trp Phe Gln Gln Asp Asn Ala Glu Glu Ser Ala Lys Lys
610 615 620
Glu Arg Ile Ala Asp Asp Ile Leu Lys Val Leu Gln Arg Arg Val Gly
625 630 635 640
Met His Gly Glu Leu Leu Val Ser Leu Ile Pro Gln Arg Lys Ala Leu
645 650 655
Gln Glu Leu Tyr Met Gln Glu Thr Pro Leu Glu Leu Pro Asp Asp Asp
660 665 670
Lys Ala Ser Asn Glu Ser Ile Ala Thr Phe Gly Ile Gly Ser Asp Phe
675 680 685
Asp Leu Phe Ser Asp Thr Ser Asp Glu Ser Ile Ser Ala Leu Ser His
690 695 700
Glu Gln Met Phe Ala Gln Gln Val Ile Lys Leu Trp Val Asn Tyr Leu
705 710 715 720
Arg Thr Val Pro Glu Gln Thr Asn Val Thr Asn Phe Ile Gly Leu Pro
725 730 735
Arg Pro Ile Ile Glu Thr Leu Val Asp Glu Leu Ile Thr Ala Ile Gln
740 745 750
Arg Met Asp Ile Glu Gly Glu Leu Val Asn Val Leu Ala Asn Thr Glu
755 760 765
Gln Ala Gly Val Arg Arg Glu Lys Met Val Glu Arg Gln Val Ser Arg
770 775 780
Val Leu Asn Val Ile Asn Asp Phe Ile Thr Trp Leu Gly Tyr Gln Lys
785 790 795 800
Ile Thr Lys Glu Lys Arg Pro Val Ser Lys Tyr Asn Lys Gly His Pro
805 810 815
Leu Phe Ser Gly Pro Asn Lys His Asp Pro Ala Leu Trp Lys Asp Asp
820 825 830
Gly His Leu Tyr Arg Leu Thr Ser Glu Pro Leu Ser Tyr Ser Ala Met
835 840 845
Phe Ile Phe Asp Trp Leu Ile Gly Leu Lys Glu Met Ile Lys Glu Asn
850 855 860
Val Gly His Ser Ala Gly Arg Glu Ile Thr Ala Ala Gln Asn Glu Arg
865 870 875 880
Leu Gly Thr Ile Ile Glu Arg Ile Gln Leu Ser Ser Glu
885 890

Claims (4)

1.三元复合毒素在制备抑制Hela细胞的药物中的用途,其特征在于,所述三元复合毒素的编码基因来源于昆虫病原线虫共生致病杆菌Xenorhabdus stockiae HN_xs01,为xsrfABC基因,xsrfABC基因包含三个开放阅读框:xsrfA、xsrfB和xsrfC,xsrfA的核苷酸序列如序列表SEQ ID NO: 1所示,xsrfB的核苷酸序列如序列表SEQ ID NO: 2所示,xsrfC的核苷酸序列如序列表SEQ ID NO: 3所示;xsrfA基因编码的蛋白氨基酸序列如序列表SEQID NO: 4所示,xsrfB基因编码的蛋白氨基酸序列如序列表SEQ ID NO: 5所示,xsrfC基因编码的蛋白氨基酸序列如序列表SEQ ID NO: 6所示。
2.根据权利要求1所述的用途,其特征在于,所述三元复合毒素的制备方法包括以下步骤:首先提取了Xenorhabdus stockiae HN_xs01的基因组,构建了基因组fosmid文库,筛选对Hela细胞具有毒性的克隆子,对克隆子进行测序分析,将xsrfABC基因克隆获得表达载体pSC101-BAD-xsrfABC,将表达载体转化入GB05,得到重组菌株GB05,诱导表达XSrfABC毒素。
3.根据权利要求2所述的用途,其特征在于,所述三元复合毒素的制备方法还包括以下步骤:分别构建了XSrfA、XSrfB和XSrfC的原核表达载体,诱导表达复合毒素的各组分,并利用亲和层析纯化毒素蛋白,将三种组分混合。
4.根据权利要求3所述的用途,其特征在于,所述三元复合毒素的制备方法还包括以下步骤:PCR分别扩增xsrfA、xsrfBxsrfC基因片段,并克隆到表达质粒pGEX-4T-2,获得三个重组质粒:pGEX-4T-srfA,pGEX-4T-srfB,pGEX-4T-srfC;
将三个重组质粒分别电转至E. coli BL21中,获得重组菌株BL21-SrfA、BL21-SrfB、BL21-SrfC;三种重组菌株经IPTG诱导后,均表达可溶性的目的蛋白;将三种可溶性表达蛋白的菌体上清用0.22 μm滤膜过滤,用清洗缓冲液清洗GST琼脂糖树脂,加入蛋白裂解液,加入5倍柱体积的洗涤缓冲液洗脱蛋白,重复洗脱一次,加入2倍柱体积Elution buffer洗脱,收集蛋白,将分别表达再收集的三种蛋白混合。
CN201711373010.XA 2017-12-19 2017-12-19 一种具有抗肿瘤活性的三元复合毒素及其制备方法 Active CN108048471B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711373010.XA CN108048471B (zh) 2017-12-19 2017-12-19 一种具有抗肿瘤活性的三元复合毒素及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711373010.XA CN108048471B (zh) 2017-12-19 2017-12-19 一种具有抗肿瘤活性的三元复合毒素及其制备方法

Publications (2)

Publication Number Publication Date
CN108048471A CN108048471A (zh) 2018-05-18
CN108048471B true CN108048471B (zh) 2021-07-20

Family

ID=62133814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711373010.XA Active CN108048471B (zh) 2017-12-19 2017-12-19 一种具有抗肿瘤活性的三元复合毒素及其制备方法

Country Status (1)

Country Link
CN (1) CN108048471B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103074282A (zh) * 2013-01-25 2013-05-01 湖南师范大学 一株肿瘤靶向细菌及其菌剂制备方法与代谢产物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103074282A (zh) * 2013-01-25 2013-05-01 湖南师范大学 一株肿瘤靶向细菌及其菌剂制备方法与代谢产物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GenBank登录号:MG755815.1;NCBI;《NCBI GenBank》;20190430;第1-7101位 *
SrfABC Toxin from Xenorhabdus stockiae Induces Cytotoxicity and Apoptosis in HeLa Cells;Yawei Sun等;《Toxins》;20191122;第11卷(第685期);第1-13页 *
SrfABC复合毒素酶活性组分及其作用机理研究;杨曦;《中国优秀硕士学位论文全文数据库 基础科学辑》;20191215(第12期);第A006-268页 *
致病杆菌中SrfABC三元毒素的细胞毒性及作用机制研究;谢亚丽;《中国优秀硕士学位论文全文数据库 基础科学辑》;20200115(第01期);第A006-846页 *
致病杆菌中SrfABC类毒素生物活性研究;胡晓凤;《中国优秀硕士学位论文全文数据库 基础科学辑》;20160415(第04期);第A006-299页 *

Also Published As

Publication number Publication date
CN108048471A (zh) 2018-05-18

Similar Documents

Publication Publication Date Title
CN109750054B (zh) 一种牛支原体蛋白基因MbovGdpP及其应用
CN110157654B (zh) 一种纳豆芽孢杆菌重组菌及其构建方法与应用
CN109055346B (zh) 一种热稳定性提高的L-天冬氨酸-α-脱羧酶
CN112029752B (zh) 一种石莼多糖裂解酶及其编码基因与应用
CN104593388B (zh) 一种鲫鱼疱疹病毒病jdorf25疫苗及制备方法和应用
CN115975004A (zh) 一种重组人纤连蛋白、其制备方法和应用
Liu et al. Identification of the genes involved in growth characters of medicinal fungus Ophiocordyceps sinensis based on Agrobacterium tumefaciens–mediated transformation
CN109536427B (zh) 一种酸胁迫抗性提高的乳酸菌工程菌
CN111499759B (zh) 一种具有细胞穿膜性的锌指蛋白-乳铁蛋白融合蛋白质及其制备与应用
EA025689B1 (ru) Способ высокой экспрессии рекомбинантного белка в генно-инженерных бактериях и его применение
CN112125960B (zh) 一种适用于大规模工厂化生产操作的去除内毒素的通用方法
CN111378638A (zh) 幽门螺旋杆菌噬菌体裂解酶及其制备方法
CN111057695B (zh) 一种腈水解酶及其制备方法和应用
CN108048471B (zh) 一种具有抗肿瘤活性的三元复合毒素及其制备方法
CN111117942B (zh) 一种产林可霉素的基因工程菌及其构建方法和应用
CN108484749B (zh) 一种重组可溶性人源骨靶向干扰素γ-1b及其制备方法
CN112195129B (zh) 紫色杆菌素生物合成基因簇及其应用
CN111876436B (zh) 一种甲硫氨酸裂解酶及其编码基因和应用
CN111705049B (zh) 新壳聚糖酶chi1、其编码基因及其应用
KR102026836B1 (ko) 토양 메타게놈 유래 신규 리파아제 유전자 Lip-1420 및 이의 용도
CN115992117B (zh) 一种重组人溶菌酶及其制备方法和应用
CN111944779B (zh) 一种海藻糖合成双功能酶编码基因TvTPS/TPP及其应用
CN113493745B (zh) 生产头孢菌素c的基因工程菌及其构建方法
CN114304192B (zh) 一种耐硼赖氨酸芽孢杆菌细菌素类似物的制备方法及在防治木薯细菌性枯萎病中的应用
CN111394295B (zh) 一种制备固定化精氨酸脱亚胺酶及生产[14/15n]-l-瓜氨酸的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant